Perioperative Atezolizumab Falls Short in TNBC
Dec 13, 2024 · Adding atezolizumab (Tecentriq) to neoadjuvant chemotherapy followed by adjuvant atezolizumab did not significantly improve event-free survival (EFS) in patients with triple-negative breast cancer (TNBC), missing the primary end point of the phase 3 NSABP B-59/GBG-96-GeparDouze trial (NCT03281954). 1 Results presented at the 2024 San Antonio Breast Cancer Symposium showed that at a median ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.
Six Tips for Identifying Go-Getters for Your Practice
Dec 16, 2024 · THERE ARE 2 types of employees: the go-getters and the “gonnas.” T he gonnas are the ones who are “gonna” get around to doing what you ask of them. They are the ones who have excuses and reasons why they didn’t do what is expected or who declare that they will try and do what is asked or expected of them.
TMB and Gene Profiles Confirm Prognostic Value in TNBC
Dec 11, 2024 · Various biomarkers, including T-cell inflamed 18-gene expression profile, were positively prognostic for improved pathologic complete response (pCR) and event-free survival (EFS), with or without the addition of pembrolizumab (Keytruda; P ≤.001), according to findings from a prespecified, exploratory analysis of the KEYNOTE-522 study (NCT03036488) in high-risk, early triple-negative breast ...
FDA Grants Zongertinib Breakthrough Therapy Designation in …
Aug 27, 2024 · Zongertinib (BI 1810631), an investigational oral therapy, was granted breakthrough therapy designation (BTD) from the FDA. China’s Center for Drug Evaluation (CDE) also granted a BTD for this agent in adult patients with advanced, unresectable or metastatic non–small cell lung cancer (NSCLC) whose tumors have activating HER2 mutations and who have received prior systemic therapy.
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
Jan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers Symposium.
FDA OKs Study of Amezalpat in Frontline Liver Cancer
Nov 13, 2024 · The clinical and regulatory team at Tempest are thrilled to receive this notice from FDA with respect to the planned pivotal phase 3 trial to evaluate amezalpat as a potential treatment for first-line liver cancer,” said Sam Whiting MD, PhD, chief medical officer and head of research and development of Tempest, in a press release. 1 “Previously reported positive phase 2 data underscore ...
Recent Approvals Signal a Bright Future for Myelodysplastic …
Dec 22, 2023 · Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...